Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cerevel Therapeutics
Biotech
AbbVie's $9B schizophrenia prospect flunks phase 2 trials
The candidate at the center of AbbVie’s $8.7 billion Cerevel acquisition has failed a pair of phase 2 trials, delivering a boost to rival BMS.
Nick Paul Taylor
Nov 11, 2024 10:06am
AbbVie Parkinson's drug from $8.7B Cerevel buyout scores
Sep 26, 2024 10:45am
Bain unveils $3B fund for life science companies
Sep 10, 2024 11:20am
AbbVie axes Alzheimer's program amid 'evolving landscape'
Jul 25, 2024 10:49am
AbbVie-bound Cerevel reports phase 3 Parkinson's victory
Apr 18, 2024 8:34am
AbbVie grabs a wrench to add immunology-focused Landos Biopharma
Mar 25, 2024 9:20am
